EverHint – Dip Bounce V2 (Reclaim) – Top 10 Signals for Oct 19, 2026
Excerpt: 10 signals (from 39 total). Technology leads (8). price range $14-$183. 2 with insider selling.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
The VIX dropping sharply to 18.44 (-7.75%) signals a meaningful compression in implied volatility, creating a favorable backdrop for dip-bounce strategies. Lower volatility typically narrows intraday price swings, which can improve the precision of reclaim setups — entries become cleaner and stop-loss levels are less likely to be triggered by erratic noise. That said, a VIX still hovering near 18 suggests the market hasn't fully shifted into complacency, meaning there's enough residual uncertainty to generate the short-term dips that dip_bounce_v2_reclaim signals are designed to exploit.
Trend direction is broadly constructive, with the Nasdaq leading at +1.11% and the S&P 500 adding +0.42%, while the Dow's slight decline (-0.07%) hints at mild rotation away from value and defensive names. This divergence reinforces a risk-on posture tilted toward growth, which aligns well with the dominant signal cluster in Technology — the sector most sensitive to momentum and liquidity conditions. When growth indices outperform, reclaim setups in high-beta sectors tend to resolve faster and with greater follow-through, boosting the probability profile of these signals.
The combination of falling volatility, a growth-led tape, and 39 signals concentrated in Technology points to a market environment where dip-buying is being rewarded. Sector rotation appears to be flowing into higher-growth areas rather than defensives, supporting the thesis that pullbacks are being viewed as opportunities rather than warnings. Traders should remain attentive to intraday momentum confirmation, as low-VIX environments can occasionally produce shallow bounces that stall quickly if broader buying conviction fades.
📊 Signals (10 of 39 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | RNG | RingCentral, Inc. | Technology | $79.19 | 0.26 | — | $5.8B |
| 2 | IRON | Disc Medicine, Inc. | Healthcare | $78.93 | 0.22 | — | $3.0B |
| 3 | CRGY | Crescent Energy Company | Energy | $13.70 | 0.20 | — | $4.5B |
| 4 | JHX | James Hardie Industrie... | Basic Materials | $25.55 | 0.20 | — | $14.8B |
| 5 | WEX | WEX Inc. | Technology | $183.26 | 0.17 | — | $6.2B |
| 6 | NRIX | Nurix Therapeutics, Inc. | Healthcare | $24.93 | 0.16 | Sell -$36,300 | $2.6B |
| 7 | AMCR | Amcor plc | Consumer Cyclical | $43.95 | 0.16 | — | $20.3B |
| 8 | PTRN | Pattern Group Inc. Ser... | Technology | $17.76 | 0.15 | — | $2.8B |
| 9 | AGIO | Agios Pharmaceuticals,... | Healthcare | $34.90 | 0.15 | — | $2.1B |
| 10 | GEF-B | Greif, Inc. | Consumer Cyclical | $111.36 | 0.14 | — | $3.8B |
Recent Headlines
IRON (Disc Medicine, Inc.)
- Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
- Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript
- Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
- Disc Medicine stock soars: take profit or buy into strength?
- Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment
- Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Enjoying the updates? Liking, sharing, or subscribing helps bring this analysis to a wider audience.